Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北控醫療健康產業集團有限公司
Beijing Enterprises Medical And Health Industry Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2389)

PROFIT WARNING

This announcement is made by Beijing Enterprises Medical and Health Industry Group Limited (the "**Company**", together with its subsidiaries as the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2019 and the information currently available to the Board, it is expected that the Group will record an increase in loss for the six months ended 30 June 2019 of not less than HK$57,000,000, as compared to the loss for the six months ended 30 June 2018. Such change is mainly due to the combined effect of followings:

(i) There was a fair value gain of the Group's investment properties in Shanghai and Beijing of approximately HK$72,040,000 in total for the last period, while there was no such gain for the current period as the fair value of those properties remained stable; and

(ii) As set out in the announcement of the Group dated 11 March 2019, the Yunnan provincial government decided to suspend the development and construction in Haidong New District of Dali City, and the property project of the Group in Dali was therefore forced to be halted. Accordingly, there was a provision for impairment of the upfront costs of the project of approximately HK$19,000,000 for the current period.

As at the date of this announcement, the Company is still in the process of finalizing its interim results for the six months ended 30 June 2019. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group, and may be subject to impairment of assets (if any), share of profits/losses of associates, the final revised fair value of investment properties and other review adjustment during the review process. The details of the interim results for the six months ended 30 June 2019 of the Group will be disclosed in the interim results announcement of the Company, which is expected to be published on 29 August 2019.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
Beijing Enterprises Medical and Health Industry Group Limited
Zhu Shi Xing
Chairman

Hong Kong, 8 August 2019

As at the date of this announcement, the Board comprises seven Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Siu Kin Wai, Mr. Hu Shiang Chi, Mr. Wang Zheng Chun and Mr. Zhang Jing Ming and five Independent Non-Executive Directors, namely Mr. Robert Winslow Koepp, Mr. Gary Zhou, Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin and Mr. Zhang Yun Zhou.